Fig. 9: Brain permeability, acute toxicity evaluation, and Y-maze assay. | Nature Communications

Fig. 9: Brain permeability, acute toxicity evaluation, and Y-maze assay.

From: Discovery of NIRF theranostic probes targeting amyloid-β and cholinesterases in Alzheimer’s disease models

Fig. 9: Brain permeability, acute toxicity evaluation, and Y-maze assay.

a PAMPA assay protocol. The bar graph illustrates the permeability efficiency of I-43 compared to reference drugs; data points represent the mean ± SD (n = 2 independent experiments, each performed in quadruplicate). b Schematic presentation for the acute oral toxicity study of I-42 and I-43. c Schematic presentation of behavioral (Y-maze) study timeline. c1 Quantitative analysis for % spontaneous alternation upon treatment with I-43 (5.0 and 10 mg/kg, via i.p. route) and I-42 (5.0 and 10 mg/kg, via i.p. route) on scopolamine-induced memory deficits in mice (mean ± SD, n = 6 independent mice, Dunnett’s post hoc test using one-way ANOVA, ****P ˂ 0.0001,***P = 0.0003, **P = 0.003, and nsp > 0.999). Source data are provided as a Source Data file.

Back to article page